Ethyl 4-methoxysalicylateCAS# 35031-00-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 35031-00-6 | SDF | Download SDF |
| PubChem ID | 13013010 | Appearance | Powder |
| Formula | C10H12O4 | M.Wt | 196.2 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | ethyl 2-hydroxy-4-methoxybenzoate | ||
| SMILES | CCOC(=O)C1=C(C=C(C=C1)OC)O | ||
| Standard InChIKey | XTIRHTFASWVFJU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H12O4/c1-3-14-10(12)8-5-4-7(13-2)6-9(8)11/h4-6,11H,3H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Ethyl 4-methoxysalicylate Dilution Calculator
Ethyl 4-methoxysalicylate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.0968 mL | 25.4842 mL | 50.9684 mL | 101.9368 mL | 127.421 mL |
| 5 mM | 1.0194 mL | 5.0968 mL | 10.1937 mL | 20.3874 mL | 25.4842 mL |
| 10 mM | 0.5097 mL | 2.5484 mL | 5.0968 mL | 10.1937 mL | 12.7421 mL |
| 50 mM | 0.1019 mL | 0.5097 mL | 1.0194 mL | 2.0387 mL | 2.5484 mL |
| 100 mM | 0.051 mL | 0.2548 mL | 0.5097 mL | 1.0194 mL | 1.2742 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Meloside A
Catalog No.:BCN2278
CAS No.:60767-80-8
- ent-Kauran-17,19-dioic acid
Catalog No.:BCN4122
CAS No.:60761-79-7
- 2-Hydroxy-1,8-cineole
Catalog No.:BCN4121
CAS No.:60761-00-4
- Canthin-6-one N-oxide
Catalog No.:BCN2992
CAS No.:60755-87-5
- AZ 10606120 dihydrochloride
Catalog No.:BCC6005
CAS No.:607378-18-7
- SB 772077B dihydrochloride
Catalog No.:BCC6116
CAS No.:607373-46-6
- Physoperuvine
Catalog No.:BCN1402
CAS No.:60723-27-5
- Myristicin
Catalog No.:BCN2730
CAS No.:607-91-0
- Sesamin
Catalog No.:BCN4123
CAS No.:607-80-7
- FC 131
Catalog No.:BCC7917
CAS No.:606968-52-9
- 3-Hydroxy-1,5-diphenyl-1-pentanone
Catalog No.:BCN3536
CAS No.:60669-64-9
- Isopicropodophyllone
Catalog No.:BCN8316
CAS No.:60660-50-6
- A 77-01
Catalog No.:BCC1318
CAS No.:607737-87-1
- SB742457
Catalog No.:BCC5058
CAS No.:607742-69-8
- Quercetin 3-O-beta-D-glucose-7-O-beta-D-gentiobioside
Catalog No.:BCN7821
CAS No.:60778-02-1
- Berbamine hydrochloride
Catalog No.:BCN2400
CAS No.:6078-17-7
- Norbraylin
Catalog No.:BCN4124
CAS No.:60796-64-7
- 5,7,8-Trimethoxycoumarin
Catalog No.:BCN4125
CAS No.:60796-65-8
- Dulcitol
Catalog No.:BCN8153
CAS No.:608-66-2
- Sinomenine HCl
Catalog No.:BCN6318
CAS No.:6080-33-7
- Lithium Citrate
Catalog No.:BCC3804
CAS No.:6080-58-6
- 4-Methoxy-1-methoxycarbonyl-beta-carboline
Catalog No.:BCN1401
CAS No.:60807-25-2
- Apremilast (CC-10004)
Catalog No.:BCC2273
CAS No.:608141-41-9
- Esculentoside B
Catalog No.:BCN5011
CAS No.:60820-94-2
Lamellar Liquid Crystal Improves the Skin Retention of 3-O-Ethyl-Ascorbic Acid and Potassium 4-Methoxysalicylate In Vitro and In Vivo for Topical Preparation.[Pubmed:26349686]
AAPS PharmSciTech. 2016 Jun;17(3):767-77.
The study aimed at increasing the skin retention of 3-O-ethyl-ascorbic acid (EA) and potassium 4-methoxysalicylate (4-MSK) via topical administration for effective skin-whitening. To achieve this goal, EA and 4-MSK were formulated into lamellar liquid crystalline (LLC) cream, and response surface methodology (RSM) was employed to optimize the formulation. Polarized light microscopy (PLM), differential scanning calorimetry (DSC), and rheological experiments were performed to confirm the presence of the LLC structure in the base of cream. In addition, a comparison analysis of the skin retention of the two drugs between the LLC cream and the common o/w (COW) cream was made through in vitro permeation and in vivo drug distribution experiments. As a result, the optimal formulation was defined as 1.2% of EA, 1.48% of 4-MSK, 14.05% of Schercemol DISM Ester (DISM) as the oil, 4.0% of Emulium(R) Delta as the emulsifier, and 3.0% of stearyl alcohol as the co-emulsifier. In comparison with the COW cream, the LLC cream significantly increased the skin retention of EA and 4-MSK both in vitro and in vivo. In conclusion, the LLC carrier serves as a promising choice for topical preparation by enhancing skin retention and providing desirable rheological characteristics.
